References of "Fogelman, I"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffect of risedronate on the risk of hip fracture in elderly women
McClung, MR; Geusens, P; Miller, PD et al

in Clinical Rheumatology (2001), 20

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
McClung, M R; Geusens, P; Miller, P D et al

in New England Journal of Medicine [=NEJM] (2001), 344(5), 333-40

BACKGROUND: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. METHODS: We studied 5445 women 70 to 79 years old who had osteoporosis ... [more ▼]

BACKGROUND: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. METHODS: We studied 5445 women 70 to 79 years old who had osteoporosis (indicated by a T score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak value in young adults [-4] or lower than -3 plus a nonskeletal risk factor for hip fracture, such as poor gait or a propensity to fall) and 3886 women at least 80 years old who had at least one nonskeletal risk factor for hip fracture or low bone mineral density at the femoral neck (T score, lower than -4 or lower than -3 plus a hip-axis length of 11.1 cm or greater). The women were randomly assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three years. The primary end point was the occurrence of hip fracture. RESULTS: Overall, the incidence of hip fracture among all the women assigned to risedronate was 2.8 percent, as compared with 3.9 percent among those assigned to placebo (relative risk, 0.7; 95 percent confidence interval, 0.6 to 0.9; P=0.02). In the group of women with osteoporosis (those 70 to 79 years old), the incidence of hip fracture among those assigned to risedronate was 1.9 percent, as compared with 3.2 percent among those assigned to placebo (relative risk, 0.6; 95 percent confidence interval, 0.4 to 0.9; P=0.009). In the group of women selected primarily on the basis of nonskeletal risk factors (those at least 80 years of age), the incidence of hip fracture was 4.2 percent among those assigned to risedronate and 5.1 percent among those assigned to placebo (P=0.35). CONCLUSIONS: Risedronate significantly reduces the risk of hip fracture among elderly women with confirmed osteoporosis but not among elderly women selected primarily on the basis of risk factors other than low bone mineral density. [less ▲]

Detailed reference viewed: 13 (11 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis with a rapid and sustained effect
Silverman, S; Geusens, P; Bensen, W et al

in Arthritis and Rheumatism (2000), 43(S1), 781

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman, I; Ribot, C; Smith, R et al

in Journal of Clinical Endocrinology and Metabolism (2000), 85(5), 1895-900

Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months ... [more ▼]

Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter. At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in the 2.5-mg group, compared with no change with placebo. Efficacy was similar in women who were less than 5 yr and more than 5 yr postmenopausal. At 24 months, risedronate (5 mg) had also increased BMD at the femoral neck and trochanter, whereas BMD decreased in the placebo group. BMD increases were seen at all three sites with risedronate (5 mg) after only 6 months of therapy. Risedronate was well tolerated; upper gastrointestinal adverse events were similar to placebo. We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Peer Reviewed
See detailRisedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density
Ribot, C; Smith, R; Fogelman, I et al

in Journal of Bone and Mineral Research (1999), 14(S1), 136

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailRisedronate is well-tolerated in women with osteoporosis
McClung, M; Eastell, R; Watts, N et al

in Journal of Bone and Mineral Research (1999), 14(S1), 538

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailRisedronate produces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass
Fogelman, I; Ribot, C; Smith, R et al

in Calcified Tissue International (1999), 64(S1), 69

Detailed reference viewed: 7 (2 ULg)